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Summary: Nucleic acids are sensed by specialized innate immune 
receptors, including a subgroup of TLRs and the family of RIG-I–like 
receptors. For example, viruses are detected based on the recogni-
tion of viral nucleic acids. Immunorecognition of viral nucleic acids 
leads to the initiation of early innate immune responses that limit 
viral replication and are essential for eliciting adaptive responses to 
virus-specific protein antigens. RNA with a triphosphate group at 
the 5′end (3pRNA) is the ligand for RIG-I.1 By using a new chemical 
approach for 5′ triphosphate oligoribonucleotide synthesis, we found 
that short double-strand conformation with base pairing of the nucle-
oside carrying the 5′ triphosphate is required for RIG-I binding. These 
results explain how RIG-I detects negative strand RNA viruses, which 
lack long double-stranded RNA but do contain panhandle, blunt, 
short double-stranded 5′ triphosphate RNA in their single-stranded 
genome.2 The crystal structure of the RIG-I CTD domain bound 
to the blunt-end of a 5′ -ppp-dsRNA was resolved. The structure, 
supported by mutation and functional studies, defines how a lysine-
rich basic cleft within the RIG-I CTD domain sequesters the 5′ -ppp 
end of the bound RNA.3 We found that a conserved histidine in 
RIG-I controls immune tolerance of 2′ O-methylated cap1 self RNA. 
Furthermore, we demonstrate that RIG-I-RNA ligand interaction 
not only activates type I IFN but also induces inflammasome activa-
tion4 and pro-apoptotic signaling.5 Based on these activities, RIG-I 
ligands are promising candidates for the therapy of viral infection 
and cancer. Specifically, cytoplasmic innate immune sensors endog-
enously expressed in all tumor cells help to overcome the limitations 
of conventional prophylactic vaccine strategies. The activation of 
the RIG-I–like helicase pathways in tumor cells can revert the immu-
nosuppressive tumor microenvironment into an immune-permissive 
state. Such immune intervention not only has the potential to turn 
tumors into tumor vaccines, it will enable tumor antigen–specific T 
cells induced through other tumor vaccination approaches to become 
effective inside otherwise immunosuppressive tumor environments.
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Summary: Angiogenesis, the development of new blood vessels, 
is a fundamental pathophysiological process. Vascular endothelial 
growth factor (VEGF)-A is a key regulator of blood vessel growth 
during embryonic development and in a variety of physiological pro-
cesses. VEGF inhibitors have been shown to block tumor growth in 
numerous preclinical models, consistent with an important role of 
VEGF-A in tumor angiogenesis. We developed a humanized anti–
VEGF-A monoclonal antibody (bevacizumab) to test the hypothesis 
that blocking VEGF-A–induced angiogenesis may result in a clini-
cal benefit in tumor patients. Bevacizumab has been approved by 
the FDA and worldwide for the treatment of several malignancies. 
Furthermore, blocking VEGF-A prevents vision loss and had a major 
impact on the progression of neovascular age-related macular degen-
eration and ischemic retinal disorders.
We have recently been studying the mechanisms of resistance to 
anti-VEGF therapies in various tumor models. These studies indicate 
that multiple pro-angiogenic mechanisms may be implicated. We 
identified factors produced by tumor-infiltrating myeloid cells or by 
fibroblasts identified as key mediators of angiogenesis. Efforts are 
ongoing to determine the translational and clinical significance of 
such findings.
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Summary: Atherosclerosis is a chronic inflammatory disease of the 
arterial wall responsible for most ischemic cardiovascular diseases. 
Circulating levels of several cytokines are associated with disease 
burden, and CRP levels predict the risk of future cardiovascular 
events. Atherosclerosis is initiated in response to various stimuli, 
mostly modified lipids. Innate immune responses involving both 
vascular and immune cells, mostly monocytes/macrophages, are 
rapidly activated in response to vascular injury, play important 
roles in vascular remodeling, and orchestrate the development of a 
more specific adaptive immunity. Most lymphocytes of atheroscle-
rotic plaques are CD4+ T cells of the Th1 cell type. They recog-
nize epitopes on native ApoB100 in a MHCII-dependent manner, 
produce interferon (IFN)-g and promote pro-atherogenic T cell 
responses. They are counter-regulated by the anti-inflammatory and 
homeostatic properties of regulatory T cells (Tregs), mainly through 
IL-10 and TGF-b–dependent pathways. The development of athero-
sclerosis is also associated with signs of B lymphocyte activation, 
particularly manifested by enhanced production of natural IgM 
type and adaptive IgG type antioxidized low-density lipoprotein 
autoantibodies. Recent studies have redefined the roles of the dif-
ferent B-cell subsets in atherosclerosis. Innate B1-cell subset protects 
against lesion development in an IgM-dependent manner (Kyaw, 
2011 #17924), whereas B2 cells promote atherosclerosis, at least 
in part through activation of adaptive T-cell responses. I will briefly 
discuss the most recent advances in our understanding of pro- and 
antiatherogenic pathways and suggest several new and promising 
immune-based therapeutic strategies to limit disease progression 
and severity.
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